COMP <GO>
ACHC vs ABBV // FORWARD P/E MULTIPLE
Acadia Healthcare Company Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ACHC 1
— ABBV 11
▲ FORWARD P/E MULTIPLE LEADER: ACHC
LAST: $29.46 (-0.17%) • MKT CAP: $2.74B
forward-pe
21.0x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACHC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACHC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.80% | 29.00% | -53.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.04% | 3.47% | -19.51 | ABBV | /fcf-yield <GO> |
| Operating Margin | -40.60% | 24.60% | -65.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -33.30% | 6.90% | -40.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.00% | 8.60% | -3.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.33 | -4.88 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.3 | 65.1 | -17.80 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.15 | -0.08 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 21.0x | 113.1x | -92.10 | ACHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.74B | $513.86B | -$511.12B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACHC REV | ABBV REV | ACHC GROSS % | ABBV GROSS % | ACHC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.31B | $61.16B | — | 70.2% | -$439.9M | $17.82B |
| FY 2024 | $3.15B | $56.33B | — | 70.0% | -$560.7M | $17.83B |
| FY 2023 | $2.93B | $54.32B | — | — | $330.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACHC // BETA 1.07
ABBV // BETA 1.15